Navigation Links
Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study

CHICAGO--(BUSINESS WIRE)--Jun 7, 2007 - Clinical results from a Phase II study presented for the first time at the American Headache Society (AHS) annual meeting showed that MK-0974, an investigational oral calcitonin gene-related peptide (CGRP) receptor antagonist, significantly improved migraine pain relief two hours after dosing compared to placebo, and the relief was sustained through 24 hours. MK-0974 was generally well tolerated in the study. Responses specific to other measures, such as migraine-associated symptoms, functional disability and use of additional rescue medications also were reported. MK-0974 is Merck's investigational medicine in Phase III clinical development for the acute treatment of migraine in adults and, if approved, may be the first in a new class of migraine treatments since the approval of the first triptan drug in 1991.

"The findings of this early-stage trial demonstrate the therapeutic potential of MK-0974 for the acute treatment of migraines," said Tony Ho, M.D., senior director of Clinical Neuroscience, Merck Research Laboratories. "Larger clinical trials, such as those now underway, will provide more insight into the efficacy and safety profile of MK-0974."

About MK-0974

MK-0974 is an antagonist of the receptor for CGRP, a primary neuropeptide involved in the pathophysiology of migraine. CGRP and its receptors are found in areas of the central and peripheral nervous system that are important for the transmission of migraine pain. During migraine attacks, CGRP activates these receptors and facilitates the transmission of pain impulses. MK-0974 blocks the binding of CGRP to receptors within these areas and thereby is believed to inhibit the transmission of pain signals that lead to migraine headaches.

Study design

The findings being presented are from a randomized, double-blind, placebo- and active-controlled dose-ranging clinical trial in patients wi
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
4. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
5. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
(Date:7/25/2014)... July 25, 2014 GrowBLOX Sciences, Inc. (OTCQB: GBLX) ... of Understanding ("MOU") with LaurelCo, LLC, an Illinois ... of both cultivation and dispensary medical marijuana licenses in the ... MOU, GBLX will acquire a 20% equity interest in LaurelCo, ... TM growing chambers, as well as all technology related ...
(Date:7/25/2014)... HOUSTON , July 25, 2014  Solanbridge Group ... has acquired the majority interest in Buzznbrewz.com and the ... been replaced with a fully executed Purchase Agreement. ... Solanbridge, stated "We are proud to have Mr. ... has decades of experience in the private sector and ...
(Date:7/25/2014)... -- IDEXX Laboratories, Inc. (NASDAQ: IDXX ) today ... increased 11% versus the prior year period to $390 ... quarter of 2014 versus the prior year period was ... 2 . Earnings per diluted share ("EPS") for the ... prior year period to $1.10."In the second quarter, we ...
Breaking Medicine Technology:GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 3Solanbridge Group Inc Announces Acquisition of Buzznbrewz.com 2IDEXX Laboratories Announces Second Quarter Results 2IDEXX Laboratories Announces Second Quarter Results 3IDEXX Laboratories Announces Second Quarter Results 4IDEXX Laboratories Announces Second Quarter Results 5IDEXX Laboratories Announces Second Quarter Results 6IDEXX Laboratories Announces Second Quarter Results 7IDEXX Laboratories Announces Second Quarter Results 8IDEXX Laboratories Announces Second Quarter Results 9IDEXX Laboratories Announces Second Quarter Results 10IDEXX Laboratories Announces Second Quarter Results 11IDEXX Laboratories Announces Second Quarter Results 12IDEXX Laboratories Announces Second Quarter Results 13IDEXX Laboratories Announces Second Quarter Results 14IDEXX Laboratories Announces Second Quarter Results 15IDEXX Laboratories Announces Second Quarter Results 16IDEXX Laboratories Announces Second Quarter Results 17IDEXX Laboratories Announces Second Quarter Results 18IDEXX Laboratories Announces Second Quarter Results 19IDEXX Laboratories Announces Second Quarter Results 20IDEXX Laboratories Announces Second Quarter Results 21IDEXX Laboratories Announces Second Quarter Results 22IDEXX Laboratories Announces Second Quarter Results 23IDEXX Laboratories Announces Second Quarter Results 24IDEXX Laboratories Announces Second Quarter Results 25IDEXX Laboratories Announces Second Quarter Results 26IDEXX Laboratories Announces Second Quarter Results 27IDEXX Laboratories Announces Second Quarter Results 28IDEXX Laboratories Announces Second Quarter Results 29IDEXX Laboratories Announces Second Quarter Results 30IDEXX Laboratories Announces Second Quarter Results 31IDEXX Laboratories Announces Second Quarter Results 32IDEXX Laboratories Announces Second Quarter Results 33
... Technology Applicable for the Detection of a Host of Amyloid Neurological ... ... Parkinson Disease, ROCKVILLE, Md., Aug. 29 Adlyfe, a ... announced today the publication of a study, "Detection of,misfolded prion protein ...
... 28 Gilbert Hospital is,the first hospital in ... in,extracorporeal shockwave lithotripsy in the fight against painful ... waves in a,non-invasive procedure to break down kidney ... System has been added to Gilbert,Hospital,s arsenal of ...
Cached Medicine Technology:Adlyfe Study on the Detection of Misfolded Proteins Published in the Journal Transfusion 2Adlyfe Study on the Detection of Misfolded Proteins Published in the Journal Transfusion 3
(Date:7/25/2014)... July 24, 2014 (HealthDay News) -- Shift workers, especially men, ... to people not on such schedules, a new study suggests. ... work on a set schedule, with shifts moving around at ... at all surprising," said one expert, Dr. Alan Manevitz, a ... "Physicians have long known that working shifts disrupts many ...
(Date:7/25/2014)... experimental anti-inflammatory drug can protect vulnerable neurons and ... Parkinson,s disease, researchers at Emory University School of ... in the Journal of Parkinson,s Disease . ... XPro1595, can reach the brain at sufficient levels ... injection, like an insulin shot. Previous studies of ...
(Date:7/25/2014)... Newyorktermlifeinsurance.org has released a new ... and traditional policies. , The newly released blog ... no medical exam life insurance plans and traditional policies. ... insurance plans to provide a simple guide for purchasing ... can now be purchased online. Although traditional plans do ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 CarePoint Health ... Dr. Edward Boylan, has joined our network, CarePoint Health ... community. Hundreds of highly skilled and experienced physicians comprise ... doctors and practices in Hudson County, representing a wide ... commitment to provide the highest quality care to patients ...
(Date:7/25/2014)... 25, 2014 The Rottenstein Law ... with over 25 years of experience advocating for ... prescription drugs, announces the launch of its new ... those who believe they have been harmed by ... offers valuable information about the severe adverse side ...
Breaking Medicine News(10 mins):Health News:Study Links Shift Work to Risk for Type 2 Diabetes 2Health News:Study Links Shift Work to Risk for Type 2 Diabetes 3Health News:Anti-inflammatory drug can prevent neuron loss in Parkinson's model 2Health News:No Medical Exam Life Insurance and Traditional Plans - Newyorktermlifeinsurance.org Provides Quotes for All Types of Life Insurance 2Health News:Dr. Boylan Joins CarePoint Health Medical Group 2Health News:Rottenstein Law Group LLP Announces Launch of Xarelto Injury Website 2
... Children exposed to chlorpyrifos-an insecticide, while in their mother’s ... by three years of age and also have a// ... in a peer-reviewed study conducted by Academy of Pediatrics. ... use in 2001, is still widely applied to agricultural ...
... Britain's heart experts are hoping to exploit the passion for ... people from the community not to delay calling// emergency help ... Asians in Britain have a 40-50 per cent higher death ... Asians are known to be reluctant to seek emergency help ...
... Meet organized by the city board of health on 5th ... use of Trans fat in the commercially prepared foods such ... Frieden, the health commissioner said, 'We hope that the board ... into consideration the concerns raised by 24,000 restaurateurs in New ...
... about chicken, which finds itself in the news, for all ... be hounded incessantly by germs. ,When Consumer reports ... 83% of the chickens were infected with either the campylobacter ... trigger diarrhea, cramping, nausea, fever, and vomiting, and can be ...
... A new study finds that the anti-craving drug, Naltrexone ... women who are trying to quit smoking appear //to ... individualized medicine, scientists are focusing on gender differences in ... Andrea King and her colleagues of the University of ...
... gained new ground to prove that your moms' advice, to eat ... best for you! If you chew your food well and take ... feeling better, says a new study. , Kathleen ... of this study. She compared the intake of calories of two ...
Cached Medicine News:Health News:Chlorpyrifos Affects Mental Development of Foetus 2Health News:British Heart Experts Use Cricket To Target South Asians 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: